Krilogy Financial LLC Has $1.22 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Krilogy Financial LLC grew its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 9.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 54,673 shares of the company’s stock after buying an additional 4,556 shares during the quarter. Krilogy Financial LLC owned 0.06% of Intellia Therapeutics worth $1,224,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Avidity Partners Management LP lifted its position in shares of Intellia Therapeutics by 18.0% during the 4th quarter. Avidity Partners Management LP now owns 447,434 shares of the company’s stock worth $13,642,000 after buying an additional 68,334 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in shares of Intellia Therapeutics by 2.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 700,228 shares of the company’s stock valued at $21,350,000 after acquiring an additional 18,987 shares during the period. Opaleye Management Inc. acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $3,019,000. Vanguard Group Inc. grew its holdings in shares of Intellia Therapeutics by 1.9% in the 4th quarter. Vanguard Group Inc. now owns 8,347,449 shares of the company’s stock worth $254,514,000 after purchasing an additional 155,579 shares during the last quarter. Finally, Comerica Bank lifted its holdings in Intellia Therapeutics by 853.6% during the 1st quarter. Comerica Bank now owns 37,105 shares of the company’s stock valued at $1,021,000 after purchasing an additional 33,214 shares during the last quarter. 88.77% of the stock is owned by institutional investors.

Analyst Ratings Changes

NTLA has been the topic of several research analyst reports. Royal Bank of Canada decreased their price objective on shares of Intellia Therapeutics from $60.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 9th. Evercore ISI raised Intellia Therapeutics to a “strong-buy” rating in a report on Friday, August 9th. BMO Capital Markets boosted their price objective on Intellia Therapeutics from $62.00 to $70.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. Canaccord Genuity Group restated a “buy” rating and set a $73.00 target price on shares of Intellia Therapeutics in a report on Thursday, June 27th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $65.00 price target on shares of Intellia Therapeutics in a report on Monday, June 24th. One analyst has rated the stock with a sell rating, four have given a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $61.58.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock traded up $0.43 during trading hours on Wednesday, reaching $23.61. 1,122,514 shares of the company’s stock traded hands, compared to its average volume of 1,541,386. Intellia Therapeutics, Inc. has a fifty-two week low of $19.37 and a fifty-two week high of $39.01. The firm’s 50 day moving average is $24.16 and its 200-day moving average is $25.16. The firm has a market capitalization of $2.28 billion, a price-to-earnings ratio of -4.40 and a beta of 1.81.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Thursday, August 8th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.29). The company had revenue of $7.00 million during the quarter, compared to analyst estimates of $19.68 million. During the same period in the previous year, the company earned ($1.40) EPS. The company’s revenue was down 48.5% compared to the same quarter last year. Analysts predict that Intellia Therapeutics, Inc. will post -4.98 EPS for the current year.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.